443 related articles for article (PubMed ID: 23792768)
1. Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.
Nicholson TM; Sehgal PD; Drew SA; Huang W; Ricke WA
Differentiation; 2013; 85(4-5):140-9. PubMed ID: 23792768
[TBL] [Abstract][Full Text] [Related]
2. Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents.
Kumar R; Verma V; Sarswat A; Maikhuri JP; Jain A; Jain RK; Sharma VL; Dalela D; Gupta G
Invest New Drugs; 2012 Apr; 30(2):582-93. PubMed ID: 21181231
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of androgen, estrogen, and progesterone receptors in benign prostatic hyperplasia.
Song L; Shen W; Zhang H; Wang Q; Wang Y; Zhou Z
Bosn J Basic Med Sci; 2016 Jul; 16(3):201-8. PubMed ID: 27294569
[TBL] [Abstract][Full Text] [Related]
4. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.
Väisänen MR; Väisänen T; Jukkola-Vuorinen A; Vuopala KS; Desmond R; Selander KS; Vaarala MH
Prostate; 2010 Jun; 70(8):817-24. PubMed ID: 20054821
[TBL] [Abstract][Full Text] [Related]
5. Tissue-specific quantification and localization of androgen and estrogen receptors in prostate cancer.
Sehgal PD; Bauman TM; Nicholson TM; Vellky JE; Ricke EA; Tang W; Xu W; Huang W; Ricke WA
Hum Pathol; 2019 Jul; 89():99-108. PubMed ID: 31054895
[TBL] [Abstract][Full Text] [Related]
6. Androgens and estrogens in benign prostatic hyperplasia: past, present and future.
Nicholson TM; Ricke WA
Differentiation; 2011; 82(4-5):184-99. PubMed ID: 21620560
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic effects of docosahexaenoic acid on oestrogen/androgen-induced benign prostatic hyperplasia in rats.
Wang C; Luo F; Zhou Y; Du X; Shi J; Zhao X; Xu Y; Zhu Y; Hong W; Zhang J
Exp Cell Res; 2016 Jul; 345(2):125-33. PubMed ID: 25849092
[TBL] [Abstract][Full Text] [Related]
8. Hormone concentration, metabolic disorders and immunoexpression of androgen and estrogen-alpha receptors in men with benign prostatic hyperplasia and testosterone deficiency syndrome.
Ryl A; Rotter I; Slojewski M; Dolegowska B; Grabowska M; Baranowska-Bosiacka I; Laszczynska M
Folia Histochem Cytobiol; 2015; 53(3):227-35. PubMed ID: 26400665
[TBL] [Abstract][Full Text] [Related]
9. Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia.
McPherson SJ; Ellem SJ; Simpson ER; Patchev V; Fritzemeier KH; Risbridger GP
Endocrinology; 2007 Feb; 148(2):566-74. PubMed ID: 17068134
[TBL] [Abstract][Full Text] [Related]
10. NF-κB and androgen receptor variant expression correlate with human BPH progression.
Austin DC; Strand DW; Love HL; Franco OE; Jang A; Grabowska MM; Miller NL; Hameed O; Clark PE; Fowke JH; Matusik RJ; Jin RJ; Hayward SW
Prostate; 2016 Apr; 76(5):491-511. PubMed ID: 26709083
[TBL] [Abstract][Full Text] [Related]
11. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
Krieg M; Bartsch W; Thomsen M; Voigt KD
J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338
[TBL] [Abstract][Full Text] [Related]
12. Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).
Lai KP; Huang CK; Fang LY; Izumi K; Lo CW; Wood R; Kindblom J; Yeh S; Chang C
Mol Endocrinol; 2013 Oct; 27(10):1617-31. PubMed ID: 23893956
[TBL] [Abstract][Full Text] [Related]
13. NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.
Austin DC; Strand DW; Love HL; Franco OE; Grabowska MM; Miller NL; Hameed O; Clark PE; Matusik RJ; Jin RJ; Hayward SW
Prostate; 2016 Aug; 76(11):1004-18. PubMed ID: 27197599
[TBL] [Abstract][Full Text] [Related]
14. The prevention and treatment effects of tanshinone IIA on oestrogen/androgen-induced benign prostatic hyperplasia in rats.
Wang C; Du X; Yang R; Liu J; Xu D; Shi J; Chen L; Shao R; Fan G; Gao X; Tian G; Zhu Y; Zhang J
J Steroid Biochem Mol Biol; 2015 Jan; 145():28-37. PubMed ID: 25290459
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of estrogen receptors in prostate and clinical correlation in men with benign prostatic hyperplasia.
Gangkak G; Bhattar R; Mittal A; Yadav SS; Tomar V; Yadav A; Mehta J
Investig Clin Urol; 2017 Mar; 58(2):117-126. PubMed ID: 28261681
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
Jin R; Forbes C; Miller NL; Strand D; Case T; Cates JM; Kim HH; Wages P; Porter NA; Mantione KM; Burke S; Mohler JL; Matusik RJ
Prostate; 2022 Oct; 82(14):1378-1388. PubMed ID: 35821619
[TBL] [Abstract][Full Text] [Related]
17. Cynomorium songaricum Rupr demonstrates phytoestrogenic or phytoandrogenic like activities that attenuates benign prostatic hyperplasia via regulating steroid 5-α-reductase.
Tao R; Miao L; Yu X; Orgah JO; Barnabas O; Chang Y; Liu E; Fan G; Gao X
J Ethnopharmacol; 2019 May; 235():65-74. PubMed ID: 30708032
[TBL] [Abstract][Full Text] [Related]
18. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development.
Lu T; Lin WJ; Izumi K; Wang X; Xu D; Fang LY; Li L; Jiang Q; Jin J; Chang C
Mol Endocrinol; 2012 Oct; 26(10):1707-15. PubMed ID: 22915828
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue.
Brolin J; Skoog L; Ekman P
Prostate; 1992; 20(4):281-95. PubMed ID: 1376911
[TBL] [Abstract][Full Text] [Related]
20. Relationship between the prostatic tissue components and natural history of benign prostatic hyperplasia.
Matsuda T; Fujime M; Suda K
Anal Quant Cytol Histol; 2006 Jun; 28(3):121-4. PubMed ID: 16786720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
